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BSTRACT
Background:
 
Itching, a typical symptom in dermatitis,
including atopic dermatitis (AD), leads to scratching. In
the present study, we investigated whether histamine-
induced itching is involved in scratching behavior seen
in NC/Nga (NC) mice, in which AD-like dermatitis is
induced spontaneously.
 
Methods:
 
The severity score of dermatitis, the number
of scratches, histamine content, activity of the histamine-
forming enzyme histidine decarboxylase (HDC), the
number of mast cells and the effect of histamine recep-
tor antagonists were examined.
 
Results:
 
We found two types of scratching behavior in
NC mice, one of a short duration (0.3–1.0 s) and the
other of a longer duration (over 1.0 s). The number of
short scratchings and HDC activity increased with age
(4–13 weeks) in parallel with the severity of dermatitis
in NC mice raised in conventional surroundings. The
number of longer-duration scratchings had increased
before any apparent development of dermatitis and
this type of scratching behavior increased at 13 weeks,
as did histamine content and mast cell number in the
skin. There were no changes in these parameters in
NC mice raised in specific pathogen-free surroundings
during the experimental period. Chlorpheniramine (a
histamine H
 
1
 
 receptor antagonist), but not histamine
H
 
2
 
 and H
 
3/4
 
 receptor antagonists, decreased the
number of short scratchings. None of the histamine
receptor antagonists decreased the number of long
scratchings, whereas tacrolimus reduced both short
and long scratching behavior.
 
Conclusions:
 
The findings of the present suggest that
histamine produced by enhanced HDC activity is
involved in the induction of short scratchings in NC
mice.
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I
 
NTRODUCTION
 
Itching that leads to scratching is a common symptom
among various forms of dermatitis, including atopic
dermatitis (AD), and, consequently, constitutes a major
diagnostic criterion.
 
1
 
 Because itching is a psychological
response to the manifestation of dermatitis, it is thought
that patients with AD may benefit from scratching behav-
ior. However, AD patients often complain of intense
itching leading to excessive scratching. Despite the
considerable increase in the number of AD patients,
the mechanism underlying the development of itching in
AD is unclear.
Histamine is a well-known endogenous amine that
exhibits a variety of effects on central and peripheral
tissues. These effects are mediated through at least four
histamine receptors: H
 
1
 
–H
 
4
 
. Stimulation of histamine H
 
1
 
receptors induces vasodilatation, increased capillary per-
meability, contractions of various smooth muscles and
itching and/or pain; thus H
 
1
 
 receptors are generally
thought to play an important role in allergy.
 
2
 
 Histamine
H
 
2
 
 receptors regulate gastric acid secretion and H
 
3
 
receptors control the release of histamine mainly in
the central nervous system.
 
3
 
 The molecular identity of the
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H
 
4
 
 receptor was recently reported
 
4
 
 and expression of this
type of receptor on eosinophils and mast cells has also
been reported.
 
5
 
 Although involvement of H
 
4
 
 receptors in
the immune system was suggested, biological knowledge
of the roles of these receptors is limited. Histamine, which
is synthesized from histidine by histidine decarboxylase
(HDC), is stored in mast cells. Generally, it has been
thought that histamine is formed in mast cells and pre-
formed (or pooled) histamine is released from mast cells.
However, histamine is also formed in cells other than
mast cells (possibly vascular endothelial cells, granulo-
cytic precursor cells and immune competent cells) via the
induction of HDC and the histamine thus formed is
released rapidly (without being stored) from the cells in
which it is produced.
 
6–9
 
NC/Nga (NC) mice, which originated from Japanese
fancy mice, have been established as an inbred strain by
Kondo 
 
et al
 
.
 
10
 
 and these mice develop eczema when kept
in conventional, but not in specific pathogen-free (SPF)
environments.
 
11
 
 The eczema manifests itself as lesions
characterized by edema, hemorrhage, erosion, dryness
and alopecia (on the ears, back, neck and facial
regions).
 
11
 
 Therefore, the development of dermatitis in
NC mice has been considered to be a model of human
AD.
 
11
 
 A method for evaluating scratching behavior in
mice was reported
 
12
 
 and our recent analyses on NC mice
demonstrated that there are two types of scratching
behavior, one of a short duration (0.3–1.0 s) and the
other of a longer duration (over 1.0 s).
 
13
 
In the present study, we examined the number of
scratchings, the severity of skin lesions, histamine content
and HDC activity in dorsal skin, as well as the number of
mast cells, during the development of dermatitis in NC
mice. In addition, we examined the effects of histamine
H
 
1
 
, H
 
2
 
 and H
 
3/4
 
 receptor antagonists on the scratching
behavior in NC mice and compared them with the effects
of tacrolimus, an immunosuppressant.
 
M
 
ETHODS
 
Animals
 
Conventional NC mice (CNV-NC) and SPF NC mice
(SPF-NC; 4-, 7-, 10-, 13- and 15-week-old, males)
were purchased from SLC (Shizuoka, Japan) and kept
in our laboratory (lights on 07.00 h; lights off 19.00 h;
controlled temperature (23 
 
±
 
 3
 
°
 
C) and humidity
55 
 
±
 
 15%). Food and tap water were provided 
 
ad libitum
 
.
All experiments complied with the Guidelines for Care
and Use of Laboratory Animals in Taisho Pharmaceutical
Co. Ltd and Tohoku University.
 
Agents
 
Tacrolimus (Prograf
 
®
 
; Fujisawa, Osaka, Japan), chlor-
pheniramine maleate (Wako, Osaka, Japan), famoti-
dine and thioperamide (Sigma-Aldrich, St Louis, MO,
USA) were used in the present study. Drugs were sus-
pended in 0.5% (w/v) sodium carboxymethyl cellulose.
 
Evaluation of dermatitis
 
The severity of the dermatitis was graded on a four-point
scale as follows: 0, no symptoms; 1, light; 2, mild;
3, severe. This scoring was allocated for the severity of
erythema (hemorrhage), edema, excoriation (erosion)
and scaling (dryness). A score of 3 was defined as the
severity seen in a given tissue in most NC mice at
15 weeks of age. The total score of the above four
symptoms for each mouse was taken as the score for the
mouse (i.e. minimum 0 and maximum 12).
 
Measurement of scratching behavior
 
Scratching was detected automatically and evaluated
objectively using Micro Act (Neuroscience, Tokyo,
Japan).
 
13
 
 Briefly, with mice anesthetized, a small magnet
(1 mm in diameter, 3 mm long) was implanted sub-
cutaneously into both hind paws at least 6 h before the
measurement of scratching behavior. The mouse was
placed in an observation chamber (11 cm in diameter,
18 cm high) that was surrounded by a round coil. The
electric current induced in the coil by the movement of
the magnets implanted in the hind paws was amplified
and recorded. Under the present experimental con-
ditions, the apparatus detected both short-duration
(0.3–1.0 s) and long-duration (> 1.0 s) scratchings
consecutively.
 
13
 
 Analysis parameters of Micro Act for
detecting waves were as follows: threshold 0.1 V; event
gap 0.2 s; duration 0.3–1.0 or over 1.0 s; maximum
frequency 20 Hz; minimum frequency 2 Hz.
 
Assay of HDC activity in skin
 
The activity of HDC was assayed using a method
reported previously,
 
14
 
 but with slight modification.
 
15
 
Briefly, mice were decapitated and the dorsal skin of
each mouse (approximately 200 mg) was removed and
stored in a jar with dry ice. Approximately two-thirds of
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the skin was put into a cooled tube with phosphorylated
cellulose (50 mg) and 2.5 mL ice-cold 0.02 mol/L phos-
phate buffer (pH 6.2) containing pyridoxal 5
 
′
 
-phosphate
(20 
 
µ
 
mol/L) and dithiothreitol (200 
 
µ
 
mol/L), then homog-
enized using an Ultra Turrax homogenizer (Janke &
Kunkel, Staufen, Germany). The supernatant obtained
after centrifugation of the homogenate (10 000 
 
g
 
 for
15 min at 4
 
°
 
C) was used as the enzyme solution. The
histamine in the tissues was bound to the phosphory-
lated cellulose and was removed almost completely from
the enzyme solution by centrifugation. Reaction mixture
(1 mL) containing the enzyme solution was incubated at
37
 
°
 
C for 14 h with histidine. After the enzyme reaction
had been terminated by the addition of 2 mL of
0.5 mol/L HClO
 
4
 
, the histamine formed during the
incubation was separated by chromatography on a
small phosphorylated cellulose column and quantified
fluorometrically. The activity of HDC was expressed as
pmol histamine formed during a 1 h period of incuba-
tion by the enzyme and contained in 1 g (wet weight) of
skin (pmol/h per g).
 
Determination of histamine
 
The remaining part of the skin used in the HDC assay was
used for measuring histamine. Histamine extracted with
0.4 mol/L HClO
 
4
 
 was separated by chromatography and
determined fluorometrically, as described previously.
 
14
Histological study
 
Toluidine blue staining of the dorsal skin was examined.
Hair on the skin was shaved off using an electric razor,
then the skin was removed and fixed in 10% buffered
formalin solution. A block of forehead skin was removed
and embedded in paraffin (by conventional methods),
cut into 3–4 
 
µ
 
m sections, stained with Toluidine blue
and the number of mast cells in the dermis counted.
 
Evaluation of histamine receptor antagonists 
on spontaneous scratching behavior
 
Before the administration of drugs, the scratching
behavior of each mouse over 24 h (15.00–15.00 h) was
measured. Just after this measurement, each test drug or
vehicle was given orally to the mouse, then the scratch-
ing behavior of the mouse was again measured for an
additional 24 h. Scratching behavior before and after
drug administration was tentatively called scratching
‘Pre’ and scratching ‘Post’, respectively. The sum of the
number of scratchings by each mouse for every 1 h was
recorded during the experiment. The effects of drugs did
not last for a long period of time and Pre scratching
numbers differed among the mice. Thus, in the present
study, the total number of Post scratchings for each
mouse for the initial 9 h (15.00–23.00 h) was expressed
as a percentage of that of the number of Pre scratchings.
 
Fig. 1
 
Development of dermatitis and increases in the scratching behavior in NC/Nga (NC) mice. (a)
 
 
 
The severity of the dermatitis
was assessed as scores, as described in the Methods, and (b)
 
 
 
short- and (c)
 
 
 
long-duration scratching behaviors were measured at
4, 7, 10 and 13 weeks of age in NC mice raised in either specific pathgoen-free (
 

 
) or conventional (
 

 
) conditions. Data are the
mean 
 
±
 
 SEM from 10 mice. *
 
P
 
 < 0.05, **
 
P
 
 < 0.01 compared with specific pathogen-free NC/Nga mice.
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Statistical analysis
 
Experimental values are given as the mean 
 
±
 
 SEM.
Differences in severity scores of dermatitis were analyzed
using Mann–Whitney 
 
U
 
-tests. Differences in scratching
behavior, HDC activity, histamine levels and the number
of mast cells were analyzed using Student’s 
 
t
 
-test or
Welch’s test after 
 
F
 
-test. The evaluation of histamine
receptor antagonists was analyzed using Student’s
 
t
 
-test or Welch’s test after 
 
F
 
-test, with Bonferroni
correction. 
 
P
 
 < 0.05 was considered to be statistically
significant.
 
R
 
ESULTS
 
Development of dermatitis in NC mice
 
In CNV-NC at age 4 weeks, no dermatitis was
detected, but dermatitis became apparent at 7 weeks
and thereafter gradually increased up to 13 weeks
(Fig. 1a). The hair on CNV-NC mice became pro-
gressively rougher, especially on the head and neck.
Erythema, hemorrhage, excoriation, erosion, scaling
and dryness were observed on the ears, face, nose and
neck. However, no such eczematous lesions developed
in SPF-NC.
 
Scratching behaviors of NC mice
 
The number of short-duration (0.3–1.0 s) and long-
duration (>1.0 s) scratchings did not increase in
SPF-NC during the experimental period. In contrast,
in CNV-NC, the number of short scratchings increased
with the age of the mouse. There was a statistical
difference between SPF-NC and CNV-NC at 7, 10 and
13 weeks of age (Fig. 1b). The number of long scratch-
ings was apparent and statistically higher in CNV-NC
than in SPF-NC throughout the experimental period
(Fig. 1c). Notably, in CNV-NC, even at 4 weeks, at
which time the development of dermatitis was not
detected, the number of long scratchings was signifi-
cantly higher than that in SPF-NC. It should also be
noted that the number of long scratchings in CNV-NC
increased markedly at 13 weeks.
 
Histidine decarboxylase activity and histamine 
content in the skin of NC mice
 
In SPF-NC, HDC activity, histamine levels and mast cell
numbers did not increase during the experimental period
(Fig. 2). In CNV-NC, HDC activity in the skin increased
with age and there was a statistical difference between
SPF-NC and CNV-NC at 7, 10 and 13 weeks (Fig. 2a).
 
Fig. 2
 
(a)
 
 
 
Histidine decarboxylase (HDC) activity, (b)
 
 
 
histamine levels and (c)
 
 
 
mast cell numbers in the skin of NC/Nga (NC) mice
raised in either specific pathgoen-free (
 

 
) or conventional (
 

 
) conditions. Mice were decapitated at 4, 7, 10 and 13 weeks and a
part of the back skin was subjected to assay of HDC activity (a) and histamine content (b). Another part of the skin was subjected to
Toluidine blue staining and the number of mast cells (c) was counted. Data are the mean 
 
±
 
 SEM from 10 mice. *
 
P
 
 < 0.05,
**
 
P
 
 < 0.01 compared with specific pathogen-free NC/Nga mice.
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The level of histamine in CNV-NC was statistically higher
than that in SPF-NC at 10 and 13 weeks (Fig. 2b). The
level of histamine in CNV-NC increased markedly at
13 weeks compared with its increase during the period
4–10 weeks (Fig. 2b).
Histological comparison of the skin of NC mice
The number of mast cells in the skin of CNV-NC was
significantly higher than that of SPF-NC only at 13 weeks
(Fig. 2c) and these changes were confirmed histologi-
cally (Fig. 3). In addition, in agreement with the results
of investigations of histamine content shown in Fig. 2b,
there was no significant difference in the number of mast
cells between SPF-NC and CNV-NC at ages of 4–10
weeks (Fig. 3).
Effects of histamine H1, H2 and H3/4 receptor 
antagonists on scratching behavior in NC mice 
with skin lesions
For evaluation of the antiscratch properties of drugs,
CNV-NC was used at 15 weeks of age, a time when
dermatitis had been established. Changes in the number
(total number for every 1 h period during 24 h) of Pre
and Post scratchings are shown in Figs 4,5, respectively.
Administration of vehicle to the mice had no detectable
effect on either short-duration (Fig. 4a) or long-duration
(Fig. 5a) scratching. Chlorpheniramine (an H1 receptor
antagonist) tended to decrease the number of short
scratchings for the initial several hours after its adminis-
tration (Fig. 4b), but its effect on the long-duration
scratching was only marginal (Fig. 5b). The effects of
famotidine (an H2 receptor antagonist) and thiopera-
mide (an H3/4 receptor antagonist) on the short-duration
(Fig. 4c,d) and long-duration (Fig. 5c,d) scratchings
were also only marginal. Tacrolimus (an immuno-
suppressant) tended to decrease the number of both
short- and long-duration scratchings (Figs 4e,5e). How-
ever, it should be noted that in this type of comparison,
the differences did not reach statistical significance.
However, when the data for Post scratchings are
compared in terms of percentage of Pre scratchings, as
described in the Methods, the effects of chlorphen-
iramine and tacrolimus on the short-duration scratch-
ings were statistically significant. Tacrolimus was also
effective at reducing the number of long-duration
scratchings (Fig. 6b). Famotidine and thioperamide
showed no significant effects on either short- or long-
duration scratchings, even in this type of comparison
(Fig. 6a,b).
DISCUSSION
The findings of the present study may be summarized as
follows:
1. Threre are two types of scratching behaviors in NC
mice, one of a short duration (0.3–1.0 s) and the
other of a long duration (over 1.0 s).
Fig. 3 Toluidine blue staining of the skin. Hair on the skin of
the back was shaved off using an electric razor and the skin was
removed and fixed in 10% buffered formalin solution. A block
of skin was removed, embedded in paraffin, cut into 3–4 µm
sections and stained with Toluidine blue. (a–d) Specific
pathogen-free NC/Nga mice and (e–h) conventional NC/Nga
mice at 4 (a,e), 7 (b,f), 10 (c,g) and 13 weeks of age (d,h).
Arrowheads indicate mast cells. Bar, 100 µm.
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2. The number of short-duration scratchings and HDC
activity increased with age (4–13 weeks) in parallel
with the severity of dermatitis in NC mice raised in
conventional surroundings.
3. The number of long-duration scratchings had
increased before any apparent development of derma-
titis and this type of scratching increased only between
10 and 13 weeks.
4. Histamine content and mast cell numbers in the skin
also increased significantly only between 10 and
13 weeks and at 13 weeks, respectively.
5. There were no changes in these parameters in NC
mice raised in SPF surroundings during the experi-
mental period.
6. A histamine H1 receptor antagonist (but not H2 and
H3/4 receptor antagonists) decreased the number of
short-duration scratchings. None of these histamine
antagonists decreased the number of long-duration
scratchings.
7. Tacrolimus (an immunosuppressant) reduced both
short- and long-duration scratchings.
We discuss these findings in the following paragraphs.
Involvement of histamine in short-duration 
scratching
Scratching aggravates skin lesions and causes more
itching.16 Histamine is a potent inducer of itching in
humans.17 The efficacy of antihistamine agents for the
treatment of itches was noted in AD patients,18 as well as
in mice,19 and various antihistamines are prescribed for
AD patients. However, there is controversy regarding the
role of histamine in AD. Patients often complain that
itching does not cease when such drugs are taken and
histamine may not be a major pruritogen in AD.20
Although some investigators did not find any, or only
marginal, effects of histamine H1 receptor antagonists,21
others have reported a significant reduction in pruritus
following administration of histamine H1 receptor antag-
onists.22 Intradermal injection of histamine into NC mice
was reported not to induce scratching, suggesting that
histamine has no important role in the spontaneous
itch–scratch response in NC mice.23 However, Inagaki
et al. indicated that high doses of histamine would
induce systemic effects, which prevent the observation of
Fig. 4 Effects of histamine H1,
H2 and H3/4 receptor antagonists
on the number of short-duration
scratchings. For evaluation of
the antiscratching properties
of drugs, conventional NC/Nga
mice at 15 weeks of age were
used. Scratching behaviors were
measured for 24 h before ()
and after () the administration
of each drug, as described in the
Methods. The number of short-
duration scratchings (0.3–1.0 s)
of mice in each group for every
1 h are averaged. Data are the
mean ± SEM for six to 12 mice.
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scratching.24 In the present study, we observed parallel
increases in skin HDC activity (but not histamine content
and the number of mast cells), dermatitis scores and the
number of short-duration scratchings. In addition, short-
duration scratchings were significantly suppressed by
the histamine H1 receptor antagonist chlorpheniramine.
These results suggest that the itches inducing short-
duration scratching are mediated, at least in part, by the
release of histamine that was newly formed via elevation
of HDC activity, although involvement of preformed
histamine released from mast cells was not excluded.
However, tacrolimus inhibited short-duration scratch-
ings. Therefore, other mechanisms inhibited by tacro-
limus are involved in the induction of short-duration
scratchings.
Elevation of HDC activity in the skin of NC 
mice during the development of dermatitis
As mentioned in the Introduction, histamine is also
formed in and released from cells other than mast cells
Fig. 5 Effects of histamine H1,
H2 and H3/4 receptor antagonists
on the number of long-duration
scratchings. Data on long-duration
scratching (>1.0 s) observed in
the experiments shown in Fig. 4
are shown for 24 h before ()
and after () the administration
of each drug. The number of
long-duration scratchings of mice
in each group for every 1 h are
averaged. Data are the mean ±
SEM for six to 12 mice.
Fig. 6 Comparison of the effects of drugs on (a) short- and
(b) long-duration scratchings as a percentage of Pre scratching.
The number of short-duration (0.3–1.0 s) and long-duration
(>1.0 s) scratchings for each mouse for the initial 9 h
(15.00–23.00 h) shown in Figs 4,5 were summed and the
values of Post scratching were expressed as a percentage of Pre
scratching. Mean values were compared among groups. Data
are the mean ± SEM for six to 12 mice. *P < 0.05, **P < 0.01
compared with vehicle.
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via induction of HDC activity in response to inflam-
matory cytokines or inflammatory materials derived from
bacteria (such as Lipopolysaccharide and peptidogly-
can).6–9 Because NC mice develop dermatitis in con-
ventional, but not SPF, environments we speculate that
microbial components may have a role in the develop-
ment of dermatitis. We assume that the enhanced
activity of HDC and the production and release of
histamine from non-mast cells in the skin, in which
microbial infection may be involved, may contribute to
the induction of short-duration scratching via histamine
H1 receptors in CNV-NC. Interestingly, however, the
application of histamine has been reported to reduce
itch ratings25 and axon reflex flares in AD patients,26
suggesting that histamine is not only an inflammatory
mediator, but also an anti-inflammatory mediator in AD.
Effects of drugs
Tacrolimus ointment is an effective drug for the treat-
ment of AD patients.27 In the present study, tacrolimus
decreased the number of both short- and long-duration
scratchings, whereas chlorpheniramine decreased only
the number of short-duration scratchings. Although
these results suggest that chlorpheniramine reduced
short-duration scratching behavior by blocking H1
receptors, antihistamines have a soporific effect and they
are anecdotally useful to relieve pruritus at night.28 In the
present study, chlorpheniramine 10 mg/kg did not show
sedative properties (data not shown). Because chlor-
pheniramine 30–100 mg/kg was most effective at
reducing both short- and long-duration scratchings
(data not shown), these findings seem to be due to its
sedative effects.
It was reported that keratinocytes have histamine H2
receptors and affect immune responses29 and H4 recep-
tors have been shown to be expressed on eosinophils and
mast cells.5 However, in the present study, famotidine
and thioperamide had only marginal effects on the short-
and long-duration scratchings.
Contribution of mast cells to dermatitis
In agreement with histamine contents in the skin, our
histological study showed that there was a marked
increase in the number of mast cells at 13 weeks
in  CNV-NC mice and no notable difference during
4–10 weeks in either SPF-NC or CNV-NC mice.
These results suggest that although the notable increase
in histamine content in the skin at 13 weeks is due to
an increase in mast cells, the mast cell is not a source
of a pruritogen for short-duration scratching. However,
it has also been reported that the inhibition of mast cell
activation resulted in suppression of the development
of dermatitis in NC mice with severe dermatitis.30,31
Because symptoms of dermatitis initially appeared as
itching (and, thus, scratching) in NC mice, it is likely
that mast cells infiltrate into the skin as a result of
scratching. Although the role of mast cells in AD
patients is unclear, mast cells may play divergent roles
in both the exacerbation of inflammation and in the
healing of wounds.32
Contribution of long-duration scratching to 
dermatitis in NC mice
Our findings that the time-course of the development of
short- and long-duration scratchings differed (the former
had already appeared even at 4 weeks of age and the
former (but not the latter) was suppressed by chlor-
pheniramine) suggest that the mechanisms of short- and
long-duration scratchings also differ. Mast cells in the
skin increase in number at a later period (13 weeks)
and, hence, may be involved in part of the long-duration
scratching behavior. We have no data concerning the
substance(s) responsible for long-duration scratching.
Because steroids and immunosuppressants (such as
tacrolimus) inhibit cytokine production by T cells33 and
interleukin-2 has been shown to play a role in causing
pruritus and inflammation in the skin of AD patients,34
more studies are needed to elucidate the mechanism
involved in long-duration scratching behavior. In addi-
tion, one possible reason why antihistamines exhibit no
discernible benefit in some patients may be because they
are ineffective at reducing the long-duration scratching
observed in NC mice.
In conclusion, the findings of the present study suggest
that histamine H1 receptors are involved in the induction
of short- but not long-duration scratching, although
the latter may be a more important target for reducing
the severity of dermatitis in NC mice or, possibly, in AD
patients.
REFERENCES
1 Williams HC. Atopic dermatitis: New information from
epidemiological studies. Br. J. Hosp. Med. 1994; 52:
409–12.
HISTAMINE-INDUCED SCRATCHING IN NC/Nga MICE 357
2 Tamaru T, Sato H, Miki I, Suzuki K, Ohmori K, Karasawa A.
Effects of orally administered olopatadine hydrochloride
on the ocular allergic reaction in rats. Allergol. Int. 2003;
52: 77–83.
3 Hill SJ, Ganellin CR, Timmerman H et al. International
Union of Pharmacology XIII. Classification of histamine
receptors. Pharmacol. Rev. 1997; 49: 253–78.
4 Oda T, Morikawa N, Saito Y, Masuho Y, Matsumoto S.
Molecular cloning and characterization of a novel type of
histamine receptor preferentially expressed in leukocytes.
J. Biol. Chem. 2000; 275: 36 781–6.
5 Hofstra CL, Desai PJ, Thurmond RL, Fung-Leung WP.
Histamine H4 receptor mediates chemotaxis and calcium
mobilization of mast cells. J. Pharmacol. Exp. Ther. 2003;
305: 1212–21.
6 Schayer RW. Relationship of induced histidine decarboxy-
lase activity and histamine synthesis to shock from stress
and from endotoxin. Am. J. Physiol. 1960; 198:
1187–92.
7 Endo Y, Suzuki R, Kumagai K. Macrophages can produce
factors capable of inducing histidine decarboxylase, a
histamine-forming enzyme, in vivo in the liver, spleen, and
lung of mice. Cell. Immunol. 1986; 97: 13–22.
8 Endo Y, Nakamura M. Active translocation of platelets
into sinusoidal and Disse spaces in the liver in response
to lipopolysaccharides, interleukin-1 and tumor necrosis
factor. Gen. Pharmacol. 1993; 24: 1039–53.
9 Scheneider E, Rolli-Derkinderen M, Arock M, Dy M.
Trends in histamine research: New functions during
immune responses and hematopoiesis. Trends Immunol.
2002; 23: 255–63.
10 Kondo K, Nagami T, Teramoto S. Differences in hema-
topoietic death among inbred strains of mice. In: Bond PV,
Sugahara T (eds). Comparative Cellular and Species
Radiosensitivity. Tokyo: Igakushoin. 1969; 20–9.
11 Matsuda H, Watanabe N, Gregory PG et al. Develop-
ment of atopic dermatitis-like skin lesion with IgE hyper-
production in NC/Nga mice. Int. Immunol. 1997; 9:
461–6.
12 Kuraishi Y, Nagasawa T, Hayashi K, Satoh M. Scratch-
ing behavior induced by pruritogenic but not algesio-
genic agents in mice. Eur. J. Pharmacol. 1995; 275:
229–33.
13 Takano N, Arai I, Kurachi M. Analysis of the spontaneous
scratching behavior by NC/Nga mice: A possible
approach to evaluate antipruritics for subjects with atopic
dermatitis. Eur. J. Pharmacol. 2003; 471: 223–8.
14 Endo Y. A simple method for the determination of
polyamines and histamine and its application to the assay
of ornithine decarboxylase and histidine decarboxylase
activities. Methods Enzymol. 1983; 94: 42–7.
15 Endo Y, Tabata T, Kuroda H, Tadano T, Matsushima K,
Watanabe M. Induction of histidine decarboxylase in
skeletal muscle in mice by electrical stimulation,
prolonged walking and interleukin-1. J. Physiol. 1998;
509: 587–98.
16 Wahlgren CF. Itch and atopic dermatitis: An overview.
J. Dermatol. 1999; 26: 770–9.
17 Jensen C, Norn S, Stahl Skov P, Espersen F, Koch C,
Permin H. Bacterial histamine release by immunological
and non-immunological lectin-mediated reactions. Allergy
1984; 39: 371–7.
18 Duse M, Merlini R, Gardenghi R, Porteri V. Oxatomide in
the treatment of atopic dermatitis. Minerva Pediatr. 1998;
50: 359–65.
19 Inagaki N, Nagao M, Nakamura N et al. Evaluation of
anti-scratch properties of oxatomide and epinastine in
mice. Eur. J. Pharmacol. 2000; 400: 73–9.
20 Wahlgren CF, Hagermark O, Bergstrom R. The antipruritic
effect of a sedative and a non-sedative antihistamine in
atopic dermatitis. Br. J. Dermatol. 1990; 122: 545–51.
21 Hanifin JM. The role of antihistamines in atopic dermatitis.
J. Allergy Clin. Immunol. 1990; 86: 666–9.
22 Langeland T, Fagertun HE, Larsen S. Therapeutic effect of
loratadine on pruritus in patients with atopic dermatitis. A
multi-crossover-designed study. Allergy 1994; 49: 22–6.
23 Yamaguchi T, Maekawa T, Nishikawa Y et al. Character-
ization of itch-associated responses of NC mice with mite-
induced chronic dermatitis. J. Dermatol. Sci. 2001; 25:
20–8.
24 Inagaki N, Nagao M, Igeta K, Kawasaki H, Kim JF,
Nagai H. Scratching behavior in various strains of mice.
Skin Pharmacol. Appl. Skin Physiol. 2001; 14: 87–96.
25 Giannetti A, Girolomoni G. Skin reactivity to neuro-
peptides in atopic dermatitis. Br. J. Dermatol. 1989; 121:
81–8.
26 Rukwied R, Lischetzki G, McGlone F, Heyer G, Schmelz M.
Mast cell mediators other than histamine induce pruritus
in atopic dermatitis patients: A dermal microdialysis study.
Br. J. Dermatol. 2000; 142: 1114–20.
27 Paller A, Eichenfield LF, Leung DY, Stewart D, Appell M.
A 12-week study of tacrolimus ointment for the treatment
of atopic dermatitis in pediatric patients. J. Am. Acad.
Dermatol. 2001; 44: 47–57.
28 Klein PA, Clark RA. An evidence-based review of the
efficacy of antihistamines in relieving pruritus in atopic
dermatitis. Arch. Dermatol. 1999; 135: 1522–5.
29 Nielsen HJ, Hammer JH. Possible role of histamine in
pathogenesis of autoimmune diseases: Implications for
immunotherapy with histamine-2 receptor antagonists.
Med. Hypotheses 1992; 39: 349–55.
30 Hashimoto Y, Kaneda Y, Takahashi N, Akashi S, Arai I,
Nakaike S. Clarithromycine inhibits the development of
dermatitis in NC/Nga mice. Chemotherapy 2003; 49:
222–8.
31 Hiroi J, Sengoku T, Morita K et al. Effect of tacrolimus
hydrate (FK-506) ointment on spontaneous dermatitis in
NC/Nga mice. Jpn J. Pharmacol. 1998; 76: 175–83.
32 Artuc M, Hermes B, Steckelings UM, Grutzkau A,
Henz BM. Mast cells and their mediators in cutaneous
wound healing: Active participants or innocent bystand-
ers? Exp. Dermatol. 1999; 8: 1–16.
358 Y HASHIMOTO ET AL.
33 Andersson J, Nagy S, Groth CG, Andersson U. Effects of
FK506 and cyclosporin A on cytokine production studied
in vitro at a single-cell level. Immunology 1992; 75:
136–42.
34 Wahlgren CF, Linder MT, Hägermark Ö, Scheynius A. Itch
and inflammation induced by intradermally injected
interleukin-2 in atopic dermatitis patients and healthy
subjects. Arch. Dermatol. Res. 1995; 287: 572–80.
